BRIDGEWATER, N.J., July 27, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that it will release its second quarter 2017 financial results on Friday, August 11, 2017, before market open.
Valeritas will hold a conference call on Friday, August 11, 2017, at 11:00 a.m. EDT to discuss the results. The dial-in numbers are (833) 235-7647 for domestic callers and (647) 689-4168 for international callers. The conference ID number is 56805537. A live webcast of the conference call will be available on the investor relations page of the Valeritas corporate website at www.valeritas.com.
If you are unable to participate during the live webcast, a replay will remain available until Valeritas reports its third quarter 2017 financial results on the investor relations page of the Valeritas corporate website at www.valeritas.com. In addition, a telephonic replay of the call will be available through August 12, 2017. The replay dial-in numbers are (800) 585-8367 for domestic callers and (416) 621-4642 for international callers. Please use the replay pin number 56805537.
About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Investor Contacts: Robert Flamm, Ph.D. / Brian Johnston The Ruth Group 646-536-7017 / 7028 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Kirsten Thomas / Cari Randall The Ruth Group 508-280-6592 / 646-536-7002 [email protected]


FDA Approves Mitapivat for Anemia in Thalassemia Patients
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Italy Fines Apple €98.6 Million Over App Store Dominance
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 



